DESTINY logo

DESTINY

De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia (DESTINY)

DESTINY

De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia (DESTINY)
Funding Bloodwise
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status Analysis/reporting
Start Date 12-Dec-2013

A trial of deescalation
and stopping treatment in chronic myeloid leukaemia patients with excellent responses to
tyrosine kinase inhibitor therapy